CN104586799A - Etoricoxib dispersible tablets and preparation method thereof - Google Patents
Etoricoxib dispersible tablets and preparation method thereof Download PDFInfo
- Publication number
- CN104586799A CN104586799A CN201510005409.7A CN201510005409A CN104586799A CN 104586799 A CN104586799 A CN 104586799A CN 201510005409 A CN201510005409 A CN 201510005409A CN 104586799 A CN104586799 A CN 104586799A
- Authority
- CN
- China
- Prior art keywords
- etoricoxib
- solid dispersion
- dispersible tablet
- disintegrating agent
- lubricant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses etoricoxib dispersible tablets and a preparation method thereof. The etoricoxib dispersible tablets are prepared by the following steps: by adopting etoricoxib as an active pharmaceutical ingredient, dissolving the active pharmaceutical ingredient and carriers in a solvent, adopting a pressure reducing and drying or spraying and drying technology to prepare into solid dispersion bodies, and then using the solid dispersion bodies to prepare into the dispersible tablets. The etoricoxib dispersible tablets disclosed by the invention have the advantages that the etoricoxib and a proper amount of carriers are adopted to be prepared into the solid dispersion bodies, so that the solubility and the dissolving-out speed of medicines are increased, the absorption of the medicines in a body is enhanced, and the bioavailability of the medicines is improved; and simultaneously, the solid dispersion bodies are prepared into the dispersible tablets, so that the compliance of administration of a patient is enhanced.
Description
Technical field
The present invention relates to a kind of pharmaceutical preparation, particularly a kind of Etoricoxib dispersible tablet and preparation method thereof of oral quick release category.
Background technology
Etoricoxib, chemical name is the chloro-6-methyl of 5--3 [4-(mesyl) phenyl]-2,3-bipyridyls, molecular formula: C
18h
15cIN
2o
2s, molecular weight: 358.84, its structure is as follows:
。
Etoricoxib is a kind of novel high selectivity cox 2 inhibitor, and it is 100 times of COX-1 to the selective inhibitory of COX-2; In vitro study shows, the selection of Etoricoxib to COX-2 be better than current other any one can COX-2 selective depressant.Etoricoxib is used for the treatment of osteoarthritis by more than 80 state approvals such as Europe, Latin America and the Asian-Pacific areas, and recommended dose is 30 mg and 60 mg, every day 1 time.Multinomial clinical studies show, Etoricoxib is to the therapeutic effect of osteo-arthritic pain and traditional NSAIDs diclofenac (50 mg every day 3 times), naproxen (500 mg, every day 2 times) suitable with cox 2 inhibitor celecoxib (200 mg, every day 1 time).Compared with treating with traditional NSAIDs, in Etoricoxib treatment, the incidence rate of upper digestive tract adverse events about reduces 500%.The research that Cunis etc. study long-term (52 weeks) safety in utilization of Etoricoxib shows, in long-term treatment Etoricoxib (60 mg/d) comparatively diclofenac (150 mg/d) less cause digestive tract adverse events, and therefore diclofenac group has more patient and stop treatment (4% and l%).In addition, compare the every days such as diclofenac sodium and need take 2 ~ 3 times, Etoricoxib every day 1 time, use more convenient, be beneficial to the compliance improving patient.
Etoricoxib goes on the market as film-coated tablet, and commodity are called ARCOXIA
?.But introduce Etoricoxib according to Bhaskar Chauhan in AAPS Pharm Sci Tech 2005 and belong to pole insoluble drug, the dissolution of the Etoricoxib sheet adopting traditional tablet manufacturing technique to prepare does not reach ideal numerical value.For improving the dissolution of Etoricoxib, researcher also takes a lot of method, Bhaskar Chauhan etc. adopts lipid as the carrier of solid dispersion in AAPS Pharm Sci Tech 2005, Etoricoxib is prepared into solid dispersion, improve the dissolution of Etoricoxib, but lipid belongs to water insoluble carrier material, want to improve stripping, also need to add water-solubility carrier.Haresh M. Patel etc. adopts the method for grinding that Etoricoxib and beta-schardinger dextrin-are prepared into complex thus improves the dissolution of Etoricoxib in Acta Pharm 2007, but the method for grinding should not realize when large production, and differences between batches are comparatively large, repeatability is poor.PATEL proposes to adopt menthol as adjuvant in Indian Journal of Pharmaceutical Sciences 2008, the mode of heating is adopted to be distilled by menthol after being prepared into tablet, aperture can be formed afterwards, be conducive to promoting that water enters tablet inside, thus disintegration of tablet is accelerated, promote Etoricoxib stripping, but, this method operating difficulties, and it is high to require to prepare granulation uniformity, produces more difficult realization.
Rheumatisant's majority is middle-aged and elderly people simultaneously, and it is comparatively difficult that some patients swallows conventional tablet.Dispersible tablet is a kind of novel form, and dispersible tablet enters water and gets final product rapid disintegrate, and dispersion forms uniform suspension, can promote the stripping of medicine, be conducive to the absorption of medicine, and onset is very fast, ensures the therapeutic effect of medicine.And dispersible tablet instructions of taking is more flexible, can swallow, also dispersible wet suit use as ordinary tablet, be especially applicable to the patient of old people and dysphagia.
Summary of the invention
Object of the present invention: easily occurring for solving Etoricoxib conventional tablet in prior art the shortcoming that stripping is low, the present invention proposes a kind of Etoricoxib dispersible tablet and preparation method thereof, to improve the dissolution rate of Etoricoxib and to ensure curative effect.
Technical scheme: for realizing above-mentioned goal of the invention, Etoricoxib dispersible tablet of the present invention is made up of the component of following weight fraction: Etoricoxib is 1 part of meter, solid dispersion carrier is 1-20 part, filler 10 ~ 30 parts, disintegrating agent 5 ~ 50 parts, antitackiness agent 1 ~ 30 part, fluidizer 0.01 ~ 10 part and lubricant 0.01 ~ 2 part.
Preferably, Etoricoxib dispersible tablet is made up of forming of following weight fraction: Etoricoxib 1 part meter, solid dispersion carrier 5-15 part, filler 15-30, disintegrating agent 15-30 part, antiplastering aid 10-20 part, fluidizer 1-5 part and lubricant 0.05-2 part.
Described solid dispersion carrier is the one in polyvidone, Polyethylene Glycol, poloxamer.
Described polyvidone be in 30 POVIDONE K 30 BP/USP 15,30 POVIDONE K 30 BP/USP 30,30 POVIDONE K 30 BP/USP 90 any one or multiple; Described Polyethylene Glycol be in Macrogol 4000, polyethylene glycol 6000 any one or multiple; Described poloxamer is any one in Pluronic/Lutrol F 44, PLURONICS F87.
Described disintegrating agent be in carboxymethylstach sodium, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose and polyvinylpolypyrrolidone any one or multiple.
Described filler be in microcrystalline Cellulose, mannitol, lactose, dextrin, Pulvis Talci, silicon dioxide, calcium sulfate and calcium hydrogen phosphate any one or multiple.
Described fluidizer be in Pulvis Talci, magnesium stearate, micropowder silica gel any one or multiple.
Described antitackiness agent be in Pulvis Talci, magnesium stearate, micropowder silica gel any one or multiple.
Described lubricant be in Pulvis Talci, magnesium stearate, micropowder silica gel any one or multiple.
The technical problem that the present invention also will solve is to provide the preparation method of above-mentioned Etoricoxib dispersible tablet, comprises the steps:
Get the Etoricoxib of 1 parts by weight, use the organic solvent dissolution Etoricoxib of 20-200 parts by weight, after add the solid dispersion carrier of 5-15 parts by weight, vigorous stirring makes it the solution being dissolved as clear, obtain Etoricoxib solution, adopt drying under reduced pressure or spray-dired method to be prepared into dry Etoricoxib solid dispersion this Etoricoxib solution, the disintegrating agent of this Etoricoxib solid dispersion and formula ratio, filler, antitackiness agent, fluidizer part and mix lubricant tabletting are obtained Etoricoxib dispersible tablet.
Described organic solvent is any one in dehydrated alcohol, 95% ethanol, acetone, ethyl acetate, dichloromethane and methanol.
The method of described organic solvent dissolution Etoricoxib is magnetic agitation, 40-80 DEG C heating, ultrasonic method and homogenizer stir in any one.
The advantage that the present invention has and good effect are: compared with prior art, the present invention is by utilizing solid dispersion medium, and adopt lyophilization or spray-dired method to prepare solid dispersion, increase dissolubility and the dissolution rate of medicine, facilitate medicine absorption in vivo, improve the bioavailability of medicine.Solid dispersion preparation is become dispersible tablet, enhances patient consumes's compliance.
Detailed description of the invention
Below in conjunction with specific embodiment, the invention will be further described, but do not limit protection scope of the present invention.
Embodiment 1
| Etoricoxib | 4.0 g |
| Polyethylene Glycol | 20.0 g |
| Mannitol (filler) | 72.0 g |
| Pulvis Talci (antiplastering aid) | 40.0 g |
| Polyvinylpolypyrrolidone (disintegrating agent) | 35.0 g |
| Microcrystalline Cellulose (filler) | 40.0 g |
| Cross-linking sodium carboxymethyl cellulose (disintegrating agent) | 25.0 g |
| Silicon dioxide (lubricant) | 2.0 g |
Its preparation method comprises the steps:
(1) by Macrogol 4000 heating and melting, after add Etoricoxib, vigorous stirring makes it the solution being dissolved as clear, obtains Etoricoxib solution, is adopted by this Etoricoxib solution cryodesiccated method to be prepared into dry Etoricoxib solid dispersion;
(2) adopt equivalent method of progressively increasing progressively to add diluent, disintegrating agent, antiplastering aid, lubricant, fluidizer, repeatedly sieve after mixing, direct compression obtains Etoricoxib dispersible tablet.
Result of the test:
Compressibility: good
Friability: conform with the regulations
Outward appearance: bright and clean attractive in appearance
Dispersing uniformity: conform with the regulations
Average dissolution: 50.25%.
Embodiment 2
| Etoricoxib | 4.0 g |
| Polyvidone | 28.0 g |
| Lactose (filler) | 30.0 g |
| Pulvis Talci (antiplastering aid) | 50.0 g |
| Carboxymethyl starch sodium (disintegrating agent) | 45.0 g |
| Microcrystalline Cellulose (filler) | 20.0 g |
| Cross-linking sodium carboxymethyl cellulose (disintegrating agent) | 41.0 g |
| Silicon dioxide (lubricant) | 4.0 g |
Its preparation method comprises the steps:
(1) get Etoricoxib, be dissolved in dehydrated alcohol, after add polyvidone, vigorous stirring makes it the solution being dissolved as clear, obtains Etoricoxib solution, is adopted by this Etoricoxib solution spray-dired method to be prepared into dry Etoricoxib solid dispersion;
(2) adopt equivalent method of progressively increasing progressively to add diluent, disintegrating agent, antiplastering aid, lubricant, fluidizer, repeatedly sieve after mixing, direct compression obtains Etoricoxib dispersible tablet.
Result of the test:
Compressibility: good
Friability: conform with the regulations
Outward appearance: bright and clean attractive in appearance
Dispersing uniformity: conform with the regulations
Average dissolution: 65.25%.
Embodiment 3
| Etoricoxib | 4.0 g |
| Polyvidone | 40.0 g |
| Dextrin (diluent) | 30.0 g |
| Micropowder silica gel (antiplastering aid) | 50.0 g |
| Polyvinylpolypyrrolidone (disintegrating agent) | 45.0 g |
| Microcrystalline Cellulose (diluent) | 30.0 g |
| Low-substituted hydroxypropyl cellulose (disintegrating agent) | 20.0 g |
| Magnesium stearate (lubricant) | 3.0 g |
Its preparation method comprises the steps:
(1) get Etoricoxib, be dissolved in dehydrated alcohol, after add polyvidone, vigorous stirring makes it the solution being dissolved as clear, obtains Etoricoxib solution, is adopted by this Etoricoxib solution spray-dired method to be prepared into dry Etoricoxib solid dispersion;
(2) adopt equivalent method of progressively increasing progressively to add diluent, disintegrating agent, antiplastering aid, lubricant, fluidizer, repeatedly sieve after mixing, direct compression obtains Etoricoxib dispersible tablet.
Result of the test:
Compressibility: good
Friability: conform with the regulations
Outward appearance: bright and clean attractive in appearance
Dispersing uniformity: conform with the regulations
Average dissolution: 70.70%.
Embodiment 4
| Etoricoxib | 4.0 g |
| Poloxamer | 48.0 g |
| Calcium hydrogen phosphate (diluent/antiplastering aid) | 15.0 g |
| Pulvis Talci (antiplastering aid/diluent) | 40.0 g |
| Polyvinylpolypyrrolidone (disintegrating agent) | 60.0 g |
| Calcium sulfate (diluent) | 21.0 g |
| Carboxymethyl starch sodium (disintegrating agent) | 40.0 g |
| Magnesium stearate (lubricant) | 2.0 g |
Its preparation method comprises the steps:
(1) by poloxamer heating and melting, add Etoricoxib, vigorous stirring makes it the solution being dissolved as clear, obtains Etoricoxib solution, adopts the method for drying under reduced pressure to be prepared into dry Etoricoxib solid dispersion this Etoricoxib solution;
(2) adopt equivalent method of progressively increasing progressively to add diluent, disintegrating agent, antiplastering aid, lubricant, fluidizer, repeatedly sieve after mixing, direct compression obtains Etoricoxib dispersible tablet.
Result of the test:
Compressibility: good
Friability: conform with the regulations
Outward appearance: bright and clean attractive in appearance
Dispersing uniformity: conform with the regulations
Average dissolution: 65.35%.
Embodiment 5
| Etoricoxib | 4.0 g |
| Polyvidone | 60.0 g |
| Calcium hydrogen phosphate (diluent/antiplastering aid) | 30.0 g |
| Pulvis Talci (antiplastering aid/diluent) | 50.0 g |
| Polyvinylpolypyrrolidone (disintegrating agent) | 60.0 g |
| Low-substituted hydroxypropyl cellulose (disintegrating agent) | 28.0 g |
| Micropowder silica gel (lubricant // antiplastering aid) | 2.0 g |
Its preparation method comprises the steps:
(1) get Etoricoxib, be dissolved in dehydrated alcohol, after add polyvidone, vigorous stirring makes it the solution being dissolved as clear, obtains Etoricoxib solution, is adopted by this Etoricoxib solution spray-dired method to be prepared into dry Etoricoxib solid dispersion;
(2) adopt equivalent method of progressively increasing progressively to add diluent, disintegrating agent, antiplastering aid, lubricant, fluidizer, repeatedly sieve after mixing, direct compression obtains Etoricoxib dispersible tablet.
Result of the test:
Compressibility: good
Friability: conform with the regulations
Outward appearance: bright and clean attractive in appearance
Dispersing uniformity: conform with the regulations
Average dissolution: 75.25%.
Embodiment 6
| Etoricoxib | 4.0 g |
| Polyethylene Glycol | 40.0 g |
| Lactose (diluent) | 30.0 g |
| Micropowder silica gel (antiplastering aid) | 50.0 g |
| Polyvinylpolypyrrolidone (disintegrating agent) | 45.0 g |
| Microcrystalline Cellulose (diluent) | 30.0 g |
| Low-substituted hydroxypropyl cellulose (disintegrating agent) | 20.0 g |
| Magnesium stearate (lubricant) | 3.0 g |
Its preparation method comprises the steps:
(1) get Etoricoxib, be dissolved in dehydrated alcohol, after will add the Etoricoxib of dissolving after Polyethylene Glycol heating and melting, vigorous stirring makes it the solution being dissolved as clear, after add tween, continue to stir 0.5-3 h, be cooled to rapidly less than 10 DEG C, after carry out lyophilization, be prepared into dry Etoricoxib solid dispersion;
(2) adopt equivalent method of progressively increasing progressively to add diluent, disintegrating agent, antiplastering aid, lubricant, fluidizer, repeatedly sieve after mixing, direct compression obtains Etoricoxib dispersible tablet.
Result of the test:
Compressibility: good
Friability: conform with the regulations
Outward appearance: bright and clean attractive in appearance
Dispersing uniformity: conform with the regulations
Average dissolution: 65.43%.
Embodiment 7
| Etoricoxib | 4.0 g |
| Poloxamer | 40.0 g |
| Tween (solubilizing agent) | 20.0 g |
| Lactose (diluent) | 30.0 g |
| Micropowder silica gel (antiplastering aid) | 50.0 g |
| Polyvinylpolypyrrolidone (disintegrating agent) | 45.0 g |
| Microcrystalline Cellulose (diluent) | 30.0 g |
| Low-substituted hydroxypropyl cellulose (disintegrating agent) | 20.0 g |
| Magnesium stearate (lubricant) | 3.0 g |
Its preparation method comprises the steps:
(1) get Etoricoxib, be dissolved in dehydrated alcohol, after will add the Etoricoxib of dissolving after PLURONICS F87 heating and melting, vigorous stirring makes it the solution being dissolved as clear, after add tween, continue to stir 0.5-3 h, be cooled to rapidly less than 10 DEG C, after carry out lyophilization, be prepared into dry Etoricoxib solid dispersion;
(2) adopt equivalent method of progressively increasing progressively to add diluent, disintegrating agent, antiplastering aid, lubricant, fluidizer, repeatedly sieve after mixing, direct compression obtains Etoricoxib dispersible tablet.
Result of the test:
Compressibility: good
Friability: conform with the regulations
Outward appearance: bright and clean attractive in appearance
Dispersing uniformity: conform with the regulations
Average dissolution: 55.77%.
Comparative example 1
| Etoricoxib | 4.0 g |
| Lactose (altogether micronization) | 40.0 g |
| Lactose (diluent) | 20.0 g |
| Pulvis Talci (diluent) | 30.0 g |
| Micropowder silica gel (antiplastering aid) | 50.0 g |
| Polyvinylpolypyrrolidone (disintegrating agent) | 45.0 g |
| Microcrystalline Cellulose (diluent) | 30.0 g |
| Low-substituted hydroxypropyl cellulose (disintegrating agent) | 20.0 g |
| Magnesium stearate (lubricant) | 3.0 g |
Its preparation method comprises the steps:
(1) get Etoricoxib and altogether Micronised lactose sieve after mixing, pulverized by pulverizer, be prepared into the common micro powder article of Etoricoxib and lactose;
(2) adopt equivalent method of progressively increasing progressively to add diluent, disintegrating agent, antiplastering aid, lubricant, fluidizer, repeatedly sieve after mixing, direct compression obtains Etoricoxib dispersible tablet.
Result of the test:
Compressibility: good
Friability: conform with the regulations
Outward appearance: bright and clean attractive in appearance
Dispersing uniformity: conform with the regulations
Average dissolution: 30.43%.
Comparative example 2
| Etoricoxib | 4.0 g |
| Mannitol (altogether micronization) | 40.0 g |
| Mannitol (diluent) | 20.0 g |
| Pulvis Talci (diluent) | 30.0 g |
| Micropowder silica gel (antiplastering aid) | 50.0 g |
| Polyvinylpolypyrrolidone (disintegrating agent) | 45.0 g |
| Microcrystalline Cellulose (diluent) | 30.0 g |
| Low-substituted hydroxypropyl cellulose (disintegrating agent) | 20.0 g |
| Magnesium stearate (lubricant) | 3.0 g |
Its preparation method comprises the steps:
(1) get Etoricoxib and altogether micronization mannitol sieve after mixing, pulverized by pulverizer, be prepared into the common micro powder article of Etoricoxib and mannitol;
(2) adopt equivalent method of progressively increasing progressively to add diluent, disintegrating agent, antiplastering aid, lubricant, fluidizer, repeatedly sieve after mixing, direct compression obtains Etoricoxib dispersible tablet.
Result of the test:
Compressibility: good
Friability: conform with the regulations
Outward appearance: bright and clean attractive in appearance
Dispersing uniformity: conform with the regulations
Average dissolution: 34.98%.
Comparative example 3
Etoricoxib dispersible tablet is formulated by following component, by 1000 consumptions:
| Etoricoxib | 4.0 g |
| Polyvidone | 12.0 g |
| Lactose (filler) | 80.0 g |
| Pulvis Talci (antiplastering aid) | 40.0 g |
| Polyvinylpolypyrrolidone (disintegrating agent) | 35.0 g |
| Microcrystalline Cellulose (filler) | 40.0 g |
| Cross-linking sodium carboxymethyl cellulose (disintegrating agent) | 25.0 g |
| Silicon dioxide (lubricant) | 2.0 g |
Its preparation method comprises the steps:
(1) get Etoricoxib, be dissolved in dehydrated alcohol, after add polyvidone, vigorous stirring makes it the solution being dissolved as clear, obtains Etoricoxib solution, is adopted by this Etoricoxib solution spray-dired method to be prepared into dry Etoricoxib solid dispersion;
(2) adopt equivalent method of progressively increasing progressively to add diluent, disintegrating agent, antiplastering aid, lubricant, fluidizer, repeatedly sieve after mixing, direct compression obtains Etoricoxib dispersible tablet.
Result of the test:
Compressibility: good
Friability: conform with the regulations
Outward appearance: bright and clean attractive in appearance
Dispersing uniformity: conform with the regulations
Average dissolution: 33.36%.
The present invention gropes through lot of experiments, first disperse medium has been screened, select polyvidone, Polyethylene Glycol, poloxamer as disperse medium respectively, can find by specific embodiment the ability polyvidone > Polyethylene Glycol > poloxamer promoting principal agent stripping as disperse medium.Secondly the preparation technology of solid dispersion has also carried out a large amount of groping property tests, first principal agent and disperse medium dissolution mechanism are screened, the method of the dissolving of ultrasonic dissolution, heating for dissolving, homogenizer and room temperature magnetic agitation is adopted to test respectively, but finally consider the needs that experimental safe and industrialization are amplified, finally determine that the method utilizing room temperature magnetic agitation dissolves dispersion liquid, then can prepare the higher solid dispersion of stripping by drying under reduced pressure or spraying dry.
In order to find the easiest method preparing solid dispersion, carry out micronization test, principal agent and mannitol, lactose have been carried out micronization, but finally can not reach the object promoting principal agent stripping.
Above embodiments of the invention have been described in detail, but described content being only preferred embodiment of the present invention, can not being considered to for limiting practical range of the present invention.All equalizations done according to the present patent application scope change and improve, and all should still belong within patent covering scope of the present invention.
Claims (8)
1. an Etoricoxib dispersible tablet, it is characterized in that, it is made up of the component of following weight fraction: Etoricoxib is 1 part of meter, solid dispersion carrier is 1-20 part, filler 10 ~ 30 parts, disintegrating agent 5 ~ 50 parts, antitackiness agent 1 ~ 30 part, fluidizer 0.01 ~ 10 part and lubricant 0.01 ~ 2 part.
2. according to claim 1, Etoricoxib dispersible tablet was made up of forming of following weight fraction: Etoricoxib 1 part meter, solid dispersion carrier 5-15 part, filler 15-30, disintegrating agent 15-30 part, antiplastering aid 10-20 part, fluidizer 1-5 part and lubricant 0.05-2 part.
3. Etoricoxib dispersible tablet according to claim 1, is characterized in that, described solid dispersion carrier is the one in polyvidone, Polyethylene Glycol, poloxamer.
4. Etoricoxib dispersible tablet according to claim 3, is characterized in that, described polyvidone be in 30 POVIDONE K 30 BP/USP 15,30 POVIDONE K 30 BP/USP 30,30 POVIDONE K 30 BP/USP 90 any one or multiple; Described Polyethylene Glycol be in Macrogol 4000, polyethylene glycol 6000 any one or multiple; Described poloxamer is any one in Pluronic/Lutrol F 44, PLURONICS F87.
5. Etoricoxib dispersible tablet according to claim 1, is characterized in that, described disintegrating agent is one or more in carboxymethylstach sodium, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose and polyvinylpolypyrrolidone; Described filler is one or more in microcrystalline Cellulose, mannitol, lactose, dextrin, Pulvis Talci, silicon dioxide, calcium sulfate and calcium hydrogen phosphate; Described fluidizer be in Pulvis Talci, magnesium stearate, micropowder silica gel any one or multiple; Described antitackiness agent be in Pulvis Talci, magnesium stearate, micropowder silica gel any one or multiple; Described lubricant be in Pulvis Talci, magnesium stearate, micropowder silica gel any one or multiple.
6. the preparation method of the Etoricoxib dispersible tablet described in any one of claim 1-4, is characterized in that, comprise the steps:
Get the Etoricoxib of 1 parts by weight, use the organic solvent dissolution Etoricoxib of 20-200 parts by weight, after add the solid dispersion carrier of 5-15 parts by weight, vigorous stirring makes it the solution being dissolved as clear, obtain Etoricoxib solution, adopt drying under reduced pressure or spray-dired method to be prepared into dry Etoricoxib solid dispersion this Etoricoxib solution, the disintegrating agent of this Etoricoxib solid dispersion and formula ratio, filler, antitackiness agent, fluidizer part and mix lubricant tabletting are obtained Etoricoxib dispersible tablet.
7. the preparation method of Etoricoxib dispersible tablet according to claim 6, is characterized in that, described organic solvent is any one in dehydrated alcohol, 95% ethanol, acetone, ethyl acetate, dichloromethane and methanol.
8. the preparation method of Etoricoxib dispersible tablet according to claim 6, is characterized in that, the method for organic solvent dissolution Etoricoxib is magnetic agitation, 40-80 DEG C heating, ultrasonic method and homogenizer stir in any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510005409.7A CN104586799A (en) | 2015-01-07 | 2015-01-07 | Etoricoxib dispersible tablets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510005409.7A CN104586799A (en) | 2015-01-07 | 2015-01-07 | Etoricoxib dispersible tablets and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104586799A true CN104586799A (en) | 2015-05-06 |
Family
ID=53113078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510005409.7A Pending CN104586799A (en) | 2015-01-07 | 2015-01-07 | Etoricoxib dispersible tablets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104586799A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250231A (en) * | 2015-11-02 | 2016-01-20 | 北京泰德制药股份有限公司 | Drug combination containing etoricoxib and preparation method thereof |
| CN107961222A (en) * | 2017-12-08 | 2018-04-27 | 佛山市弘泰药物研发有限公司 | A kind of Etoricoxib dispersible tablet and preparation method thereof |
| CN108057025A (en) * | 2017-12-08 | 2018-05-22 | 佛山市弘泰药物研发有限公司 | A kind of Etoricoxib oral disintegrating tablet and preparation method thereof |
| WO2019130049A1 (en) | 2017-12-29 | 2019-07-04 | Grünenthal GmbH | Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain |
| CN117982495A (en) * | 2024-04-07 | 2024-05-07 | 国药集团川抗制药有限公司 | Everolimus solid dispersion, preparation method thereof and everolimus tablet |
-
2015
- 2015-01-07 CN CN201510005409.7A patent/CN104586799A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250231A (en) * | 2015-11-02 | 2016-01-20 | 北京泰德制药股份有限公司 | Drug combination containing etoricoxib and preparation method thereof |
| CN105250231B (en) * | 2015-11-02 | 2020-05-12 | 北京泰德制药股份有限公司 | Pharmaceutical composition containing etoricoxib and preparation method thereof |
| CN107961222A (en) * | 2017-12-08 | 2018-04-27 | 佛山市弘泰药物研发有限公司 | A kind of Etoricoxib dispersible tablet and preparation method thereof |
| CN108057025A (en) * | 2017-12-08 | 2018-05-22 | 佛山市弘泰药物研发有限公司 | A kind of Etoricoxib oral disintegrating tablet and preparation method thereof |
| WO2019130049A1 (en) | 2017-12-29 | 2019-07-04 | Grünenthal GmbH | Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain |
| CN117982495A (en) * | 2024-04-07 | 2024-05-07 | 国药集团川抗制药有限公司 | Everolimus solid dispersion, preparation method thereof and everolimus tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102946869B (en) | The quick releasing formulation of gamma-hydroxybutyric acid and dosage form | |
| CN104586799A (en) | Etoricoxib dispersible tablets and preparation method thereof | |
| Ma et al. | Novel nanocrystal-based solid dispersion with high drug loading, enhanced dissolution, and bioavailability of andrographolide | |
| WO2018108152A1 (en) | Olaparib oral sustained and controlled release pharmaceutical composition and uses thereof | |
| CN109223725A (en) | For with the pharmaceutical composition containing dimethyl fumarate of low daily dose application | |
| SK1732002A3 (en) | Beta-carboline pharmaceutical compositions | |
| WO2018108157A1 (en) | Rucaparib oral sustained/controlled release pharmaceutical composition and use thereof | |
| CN104523695A (en) | Pharmaceutical composition for treating excessive proliferation diseases | |
| CN105412036A (en) | Brexpiprazole orally disintegrating tablets | |
| CN107913256A (en) | A kind of macitentan oral disnitegration tablet for treating pulmonary hypertension and preparation method thereof | |
| CN104146978A (en) | Disulfiram enteric coated tablet and preparation method thereof | |
| CN104706604A (en) | Perampanel freeze-dried oral disintegrating tablet and preparation method thereof | |
| CN101862333B (en) | Stable sodium levofolinate oral preparation and preparation method thereof | |
| CN105534932A (en) | Preparation for improving release efficiency | |
| CN105796567B (en) | Cetilistat solid dispersion and pharmaceutical preparation thereof | |
| CN103222964B (en) | Orlistat oral preparation and preparation method thereof | |
| CN109646417B (en) | Trimetazidine sustained release tablet and preparation method thereof | |
| CN104415054A (en) | Preparation method of quickly-releasing compounded paracetamol and amantadine hydrochloride tablet | |
| TW202341973A (en) | Therapeutic compounds, formulations, and use thereof | |
| CN102727456A (en) | Orally disintegrating tablet of poorly water-soluble drugs and method for preparing orally disintegrating tablet | |
| CN1899275B (en) | Use of composition of rheinic acid or rheinic acid compounds in preparing medicine for treating osteoarthritis | |
| CN101829070A (en) | Clarithromycin slow-release dispersible tablets and preparation method thereof | |
| CN104644583A (en) | Dabigatran-containing multi-unit pellet tablet and preparation thereof | |
| CN105412037B (en) | A kind of roxithromycin sustained-release preparation | |
| CN103599092B (en) | Idebebone medicinal premix, preparation method thereof and pharmaceutical preparation containing premix |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150506 |
|
| WD01 | Invention patent application deemed withdrawn after publication |